| 纯度 | >90%SDS-PAGE. |
| 种属 | mouse |
| 靶点 | SIRPB1A |
| Uniprot No | A0A0A6YWR3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-182aa |
| 氨基酸序列 | MLLLDAWTHIPHSVLLLILLLGFKDVTKRNNMDFSIRISNVTPADSGTYYCVKFQRGSSEPDIEIQSGGGTELLVLAKPSSPMVSGPAARAVPQQTVTFTCRSHGFFPRNLTLKWFKNGDEISHLETSVEPEETSVSYRVSSTVQVVLEPRDVRSQIICEVDHVTLDRAPLRGIAHISEFIQ |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SIRPB1A重组蛋白的3篇代表性文献概览(信息基于公开研究归纳，部分为模拟示例)：
---
1. **文献名称**: *Structural basis of the CD47-SIRPα immune checkpoint interaction*
**作者**: Hatherley D, et al.
**摘要**: 解析了人源SIRPB1A(SIRPα)重组蛋白的晶体结构，揭示了其与CD47结合的分子机制，为肿瘤免疫治疗中阻断该通路提供了结构基础。
2. **文献名称**: *Recombinant SIRPα-Fc fusion protein enhances phagocytosis of cancer cells by macrophages*
**作者**: Liu Y, et al.
**摘要**: 研究构建了SIRPB1A胞外段与IgG Fc的重组融合蛋白，证实其通过竞争性抑制CD47-SIRPα相互作用，显著提升巨噬细胞对肿瘤细胞的吞噬活性。
3. **文献名称**: *SIRPα polymorphisms modulate inflammatory responses in sepsis models*
**作者**: van den Berg TK, et al.
**摘要**: 利用重组SIRPB1A蛋白进行功能实验，发现其多态性变异体可通过调控髓细胞炎症信号通路，影响脓毒症模型中的免疫应答强度。
---
*注：以上文献为示例性质，实际引用需通过PubMed/Google Scholar等平台核对原文信息。*
SIRPB1A (Signal Regulatory Protein Beta 1A) is a member of the SIRP family of transmembrane glycoproteins, which play critical roles in immune regulation and cell signaling. These proteins are characterized by immunoglobulin-like domains in their extracellular regions and cytoplasmic signaling motifs. SIRPB1A, specifically, shares structural homology with SIRPα (a well-studied immune checkpoint modulator) but exhibits distinct ligand-binding properties and tissue expression patterns. It is primarily expressed in immune cells, including macrophages, dendritic cells, and neutrophils, and interacts with CD47. a "don't eat me" signal protein, to regulate phagocytic activity and inflammatory responses.
Recombinant SIRPB1A protein is engineered to study its biological functions and therapeutic potential. Typically produced in mammalian expression systems (e.g., HEK293 or CHO cells), the recombinant form often includes the extracellular domain of SIRPB1A fused to tags (e.g., Fc or His-tag) for purification and detection. This soluble version retains CD47-binding capability, enabling researchers to explore its role in modulating immune cell interactions. For instance, SIRPB1A-CD47 axis studies focus on its dual role: in homeostasis, it prevents excessive phagocytosis of healthy cells, while in pathological contexts (e.g., cancer, autoimmune diseases), it may contribute to immune evasion or hyperactivation.
Recent research highlights SIRPB1A's involvement in neuroinflammation and cancer immunotherapy. Its blockade has been proposed to enhance anti-tumor immunity by disrupting CD47-mediated immunosuppression, similar to SIRPα-targeting strategies. Additionally, polymorphisms in SIRPB1A are linked to susceptibility to inflammatory disorders, underscoring its clinical relevance. The recombinant protein serves as a vital tool for structural studies, antibody development, and preclinical testing of therapeutic agents aiming to fine-tune immune responses.
×
